Shaping national networks to improve patient access to advanced therapy medicinal products in Europe

• National networks are being established in Europe to improve patient access to advanced therapy medicinal products. • This review outlines these emerging advanced therapy medicinal product networks and their key learnings so far. • Sustainable advanced therapy medicinal product networks need inclusive governance and long-term funding models. • Systematic stakeholder diversity, inclusivity and trust are a must for effectiveness. • European collaboration between networks is key to increasing global competitiveness. Advanced therapy medicinal products (ATMPs) offer the potential to address unmet medical needs, yet ensuring sustainable patient access remains challenging. In response, national ATMP networks are being established across Europe to strengthen ATMP development, cooperation between stakeholders and patient access. This targeted review provides an overview of (emerging) national ATMP networks across Europe and reflects on learnings and best practices. Drawing on insights from a Dutch multistakeholder workshop, a targeted European survey and interviews with established networks in the UK, Sweden and Ireland, this review concludes with recommendations to support the establishment of ATMP networks and improve patient access to ATMPs.